Evidence map›Paper›PMID 37484958›Full record

ArticleFrontiers in endocrinology2023

Efficacy and safety of high-dose intramuscular vitamin D

Tao Chen, Xiaoyan Xing, Lihua Huang, Mei Tu, Xiaoli Lai, Shidi Wen, Jin Cai, Shenglong Lin, Youping Zheng, Yuehui Lin and 5 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Tao ChenDepartment of Endocrinology, Clinical Research Center for Metabolic Diseases of Fujian Province, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Xiaoyan XingDepartment of Endocrinology and Metabolism, China-Japan Friendship Hospital, Beijing, China.
Lihua HuangDepartment of Tumor Radiotherapy, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Mei TuDepartment of Endocrinology and Metabolism, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Xiaoli LaiDepartment of Endocrinology and Metabolism, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Shidi WenDepartment of Endocrinology and Metabolism, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Jin CaiDepartment of Endocrinology and Metabolism, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Shenglong LinDepartment of Severe Liver Disease, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Youping ZhengDepartment of Ultrasound, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Yuehui LinDepartment of Endocrinology and Metabolism, Longyan Traditional Chinese Medicine Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Longyan, China.
Lijuan XuDepartment of Endocrinology and Metabolism, Longyan Traditional Chinese Medicine Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Longyan, China.
Yuwen QiuDepartment of Endocrinology and Metabolism, Longyan Shanghang County Hospital, Longyan, China.
Lumin QiuDepartment of Endocrinology and Metabolism, Longyan Shanghang County Hospital, Longyan, China.
Yuebo XuDepartment of Diabetes, Longyan Boai Hospital, Longyan, China.
Peiwen WuDepartment of Endocrinology, Clinical Research Center for Metabolic Diseases of Fujian Province, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
First Affiliated Hospital of Fujian Medical University · CNFujian Medical University · CNFujian University of Traditional Chinese Medicine · CNLongyan University · CNBoai Hospital of Zhongshan · CNChina-Japan Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Distal symmetric polyneuropathy (DSPN) is the most common chronic complication of type 2 diabetes mellitus (T2DM). DSPN may lead to more serious complications, such as diabetic foot ulcer, amputation, and reduced life expectancy. Observational studies have suggested that vitamin D deficiency may be associated with the development of DSPN in T2DM. However, interventional studies have found that low-dose vitamin D supplementation does not significantly improve neuropathy in DSPN. This study aims to evaluate the efficacy and safety of intramuscular injection of high-dose vitamin D (HDVD) in T2DM with DSPN combined with vitamin D insufficiency. Methods and analysis: We will conduct a multicenter, randomized, double-blinded, and placebo-controlled trial in four large hospitals. All eligible participants will be randomly assigned to either the vitamin D Discussion: Glycemic control alone does not prevent the progression of DSPN in T2DM. Some studies have suggested that vitamin D may improve DSPN; however, the exact dose, method, and duration of vitamin D supplementation are unknown. Additionally, neuropathy repair requires HDVD supplementation to sustain adequate vitamin D levels. This once-a-month intramuscular method avoids daily medication; therefore, compliance is high. This study will be the first randomized controlled trial in China to analyze the efficacy and safety of HDVD supplementation for patients with T2DM and DSPN and will provide new ideas for pharmacological research and clinical treatment of diabetic neuropathy. Clinical trial registration: https://www.chictr.org.cn/, identifier ChiCTR2200062266.

Indexed as

Diabetes Mellitus, Type 2PolyneuropathiesVitamin D DeficiencyDouble-Blind MethodHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicVitamin DVitaminsVitamin DVitaminsdistal symmetric polyneuropathyhigh-dose vitamin D supplementationMichigan neuropathy screening instrumentrandomized controlled trialtype 2 diabetes mellitus

Identifiers

PMID37484958
PMCPMC10361572
OpenAlexW4383533557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.